| Schedule of Changes in Investments |
The following table summarizes the
changes in investments for the six months ended June 30, 2025 and year ended December 31, 2024:
| | |
Public
Company
Investment | | |
Private
Company
Investment | | |
Convertible
Debenture | | |
Total | |
| Balance, December 31, 2023 | |
$ | - | | |
| - | | |
| - | | |
| - | |
| Purchases | |
| - | | |
| 139,084 | | |
| - | | |
| 139,084 | |
| Balance, December 31, 2024 | |
$ | - | | |
| 139,084 | | |
| - | | |
| 139,084 | |
| Purchases | |
$ | 870,100 | | |
| - | | |
| 125,000 | | |
| 995,100 | |
| Transfer | |
| 139,084 | | |
| (139,084 | ) | |
| - | | |
| - | |
| Acquired in the sale of Skincare business | |
| 728,550 | | |
| - | | |
| - | | |
| 728,550 | |
| Proceeds on sale | |
| (1,109,921 | ) | |
| - | | |
| - | | |
| (1,109,921 | ) |
| Interest | |
| - | | |
| - | | |
| 4,620 | | |
| 4,620 | |
| Realized loss | |
| (371,494 | ) | |
| - | | |
| - | | |
| (371,494 | ) |
| Unrealized loss | |
| 56,305 | | |
| - | | |
| 182,594 | | |
| 238,899 | |
| Balance, June 30, 2025 | |
$ | 312,624 | | |
| - | | |
| 312,214 | | |
| 624,838 | |
|
| Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis |
The following table presents the Company’s financial
instruments measured at fair value on a recurring basis as of June 30, 2025, in accordance with the fair value hierarchy of ASC 820:
| Fair Value Measurement
Using: | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
| Equity securities | |
$ | 312,624 | | |
| – | | |
| – | | |
| 312,624 | |
| Convertible debenture | |
| - | | |
| 312,214 | | |
| – | | |
| 312,214 | |
| Total | |
$ | 312,624 | | |
| 312,214 | | |
| – | | |
| 624,838 | |
|